Press Releases

Press Releases

SAN DIEGO , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare Conference Wednesday, November 16, 2022 , at 4:25 p.m. GMT ( 11:25 a.m.
Nov 09, 2022
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe ; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for the third quarter of
Oct 27, 2022
SAN DIEGO , Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022 , after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
Oct 20, 2022